Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1985 Apr;38(4):433–437. doi: 10.1136/jcp.38.4.433

Studies on the procurement of blood coagulation factor VIII: effects of plasma freezing rate and storage conditions on cryoprecipitate quality.

A Farrugia, C Prowse
PMCID: PMC499172  PMID: 3921572

Abstract

Plasma was frozen and stored in different ways before processing to cryoprecipitate by a standard thawing technique. Freezing rate was found to be important with slow freezing having a deleterious effect on cryoprecipitate quality. Storage of frozen plasma at constant temperatures for periods up to six months had no effect on the quality of cryoprecipitate, with no difference being found for plasma stored at -20 degrees C or -40 degrees C. Subjecting frozen plasma to deliberate temperature fluctuations resulted in a considerable increase in the amount of fibrinogen recovered in cryoprecipitate, with the factor VIII yield being relatively unaffected.

Full text

PDF
433

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aledort L. M. Current concepts in diagnosis and management of hemophilia. Hosp Pract (Off Ed) 1982 Oct;17(10):77-84, 89-92. doi: 10.1080/21548331.1982.11702390. [DOI] [PubMed] [Google Scholar]
  2. BRINKHOUS K. M., PENICK G. D. Relative stability of plasma antihemophilic factor (AHF) under different conditions of storage. Am J Med Sci. 1956 Oct;232(4):434–442. doi: 10.1097/00000441-195610000-00010. [DOI] [PubMed] [Google Scholar]
  3. Brown D. L., Hardisty R. M., Kosoy M. H., Bracken C. Antihaemophilic globulin: preparation by an improved cryoprecipitation method and clinical use. Br Med J. 1967 Apr 8;2(5544):79–85. doi: 10.1136/bmj.2.5544.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chirnside A., Urbaniak S. J., Prowse C. V., Keller A. J. Coagulation abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. Br J Haematol. 1981 Aug;48(4):627–634. doi: 10.1111/j.1365-2141.1981.00627.x. [DOI] [PubMed] [Google Scholar]
  5. Hershgold E. J., Pool J. G., Pappenhagen A. R. The potent antihemophilic globulin concentrate derived from a cold insoluble fraction of human plasma: characterization and further data on preparation and clinical trial. J Lab Clin Med. 1966 Jan;67(1):23–32. [PubMed] [Google Scholar]
  6. Mason E. C., Pepper D. S., Griffin B. Production of cryoprecipitate of intermediate purity in a closed system thaw-siphon process. Thromb Haemost. 1981 Aug 28;46(2):543–546. [PubMed] [Google Scholar]
  7. Mason E. C. Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet. 1978 Jul 1;2(8079):15–17. doi: 10.1016/s0140-6736(78)91324-7. [DOI] [PubMed] [Google Scholar]
  8. Newman J., Johnson A. J., Karpatkin M. H., Puszkin S. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates. Br J Haematol. 1971 Jul;21(1):1–20. doi: 10.1111/j.1365-2141.1971.tb03413.x. [DOI] [PubMed] [Google Scholar]
  9. Over J., Bouma B. N., van Mourik J. A., Sixma J. J., Vlooswijk R., Bakker-Woudenberg I. Heterogeneity of human factor VIII. I. Characterization of factor VIII present in the supernatant of cryoprecipitate. J Lab Clin Med. 1978 Jan;91(1):32–46. [PubMed] [Google Scholar]
  10. POOL J. G., ROBINSON J. Observations on plasma banking and transfusion procedures for haemophilic patients using a quantitative assay for antihaemophilic globulin (AHG). Br J Haematol. 1959 Jan;5(1):24–30. doi: 10.1111/j.1365-2141.1959.tb04010.x. [DOI] [PubMed] [Google Scholar]
  11. Pool J. G., Shannon A. E. Production of high-potency concentrates of antihemophilic globulin in a closed-bag system. N Engl J Med. 1965 Dec 30;273(27):1443–1447. doi: 10.1056/NEJM196512302732701. [DOI] [PubMed] [Google Scholar]
  12. Prowse C. V., McGill A. Evaluation of the 'Mason' (continuous-thaw-siphon) method for cryoprecipitate production. Vox Sang. 1979;37(4):235–243. doi: 10.1111/j.1423-0410.1979.tb02297.x. [DOI] [PubMed] [Google Scholar]
  13. Rizza C. R., Spooner R. J. Treatment of haemophilia and related disorders in Britain and Northern Ireland during 1976-80: report on behalf of the directors of haemophilia centres in the United Kingdom. Br Med J (Clin Res Ed) 1983 Mar 19;286(6369):929–933. doi: 10.1136/bmj.286.6369.929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rock G. A., Tittley P. The effects of temperature variations on cryoprecipitate. Transfusion. 1979 Jan-Feb;19(1):86–89. doi: 10.1046/j.1537-2995.1979.19179160274.x. [DOI] [PubMed] [Google Scholar]
  15. Rotblat F., Tuddenham E. G. Immunologic studies of factor VIII coagulant activity (VIII:C) 1. Assays based on a haemophilic and an acquired antibody to VIII:C. 1981 Feb 15-Mar 1Thromb Res. 21(4-5):431–445. doi: 10.1016/0049-3848(81)90144-4. [DOI] [PubMed] [Google Scholar]
  16. Slichter S. J., Counts R. B., Henderson R., Harker L. A. Preparation of cryoprecipitated factor VIII concentrates. Transfusion. 1976 Nov-Dec;16(6):616–626. doi: 10.1046/j.1537-2995.1976.16677060245.x. [DOI] [PubMed] [Google Scholar]
  17. Smit Sibinga C. T., Das P. C. Heparin and factor VIII. Scand J Haematol Suppl. 1984;40:111–122. doi: 10.1111/j.1600-0609.1984.tb02552.x. [DOI] [PubMed] [Google Scholar]
  18. Vermeer C., Soute B. A., Ates G., Brummelhuis H. G. Contribution to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma. Vox Sang. 1976;30(1):1–22. doi: 10.1111/j.1423-0410.1976.tb04830.x. [DOI] [PubMed] [Google Scholar]
  19. Wensley R. T., Snape T. J. Preparation of improved cryoprecipitated factor VIII concentrate. A controlled study of three variables affecting the yield. Vox Sang. 1980;38(4):222–228. doi: 10.1111/j.1423-0410.1980.tb02358.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES